ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $57.62 million. The enterprise value is $67.34 million.
Important Dates
The last earnings date was Wednesday, March 4, 2026, after market close.
| Earnings Date | Mar 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 9.05 million shares outstanding. The number of shares has increased by 10.52% in one year.
| Current Share Class | 9.05M |
| Shares Outstanding | 9.05M |
| Shares Change (YoY) | +10.52% |
| Shares Change (QoQ) | +1.60% |
| Owned by Insiders (%) | 28.06% |
| Owned by Institutions (%) | 18.22% |
| Float | 6.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.08 |
| Forward PS | n/a |
| PB Ratio | 1.93 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.44 |
| EV / EBITDA | 15.49 |
| EV / EBIT | 40.84 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 3.13 |
| Debt / FCF | n/a |
| Interest Coverage | 3.76 |
Financial Efficiency
Return on equity (ROE) is -3.63% and return on invested capital (ROIC) is 4.17%.
| Return on Equity (ROE) | -3.63% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 4.17% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 5.26% |
| Revenue Per Employee | $329,095 |
| Profits Per Employee | -$12,381 |
| Employee Count | 84 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ImmuCell has paid $11,000 in taxes.
| Income Tax | 11,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.71% in the last 52 weeks. The beta is 0.30, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +32.71% |
| 50-Day Moving Average | 6.42 |
| 200-Day Moving Average | 6.24 |
| Relative Strength Index (RSI) | 47.07 |
| Average Volume (20 Days) | 11,392 |
Short Selling Information
The latest short interest is 15,924, so 0.18% of the outstanding shares have been sold short.
| Short Interest | 15,924 |
| Short Previous Month | 18,071 |
| Short % of Shares Out | 0.18% |
| Short % of Float | 0.27% |
| Short Ratio (days to cover) | 0.24 |
Income Statement
In the last 12 months, ImmuCell had revenue of $27.64 million and -$1.04 million in losses. Loss per share was -$0.12.
| Revenue | 27.64M |
| Gross Profit | 11.45M |
| Operating Income | 1.65M |
| Pretax Income | -1.03M |
| Net Income | -1.04M |
| EBITDA | 4.35M |
| EBIT | 1.65M |
| Loss Per Share | -$0.12 |
Full Income StatementBalance Sheet
The company has $3.89 million in cash and $13.61 million in debt, with a net cash position of -$9.72 million or -$1.07 per share.
| Cash & Cash Equivalents | 3.89M |
| Total Debt | 13.61M |
| Net Cash | -9.72M |
| Net Cash Per Share | -$1.07 |
| Equity (Book Value) | 29.80M |
| Book Value Per Share | 3.29 |
| Working Capital | n/a |
Full Balance SheetMargins
Gross margin is 41.40%, with operating and profit margins of 5.97% and -3.76%.
| Gross Margin | 41.40% |
| Operating Margin | 5.97% |
| Pretax Margin | -3.72% |
| Profit Margin | -3.76% |
| EBITDA Margin | 15.72% |
| EBIT Margin | 5.97% |
| FCF Margin | n/a |
